At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Hybrid fractional laser +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Prospective, Blinded Study to Evaluate the Efficacy and Safety of a Tripeptide/Hexapeptide Topical When Used With Er:YAG Hybrid Laser for the Treatment of Acne Scars
In Brief
A clinical study evaluating Hybrid fractional laser, Alastin Regenerating Skin Nectar with TriHex Technology, and 1 other intervention for Acne Scars - Mixed Atrophic and Hypertrophic. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartFeb 2020
First PostedOct 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedOct 28, 2020
Enrollment StartFeb 13, 2020
Primary CompletionJun 18, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.7 years ago
Interventions
Hybrid fractional laserdevice
two treatments given one month apart
Alastin Regenerating Skin Nectar with TriHex Technologyother
applied twice daily
Cetaphil face creamother
applied twice daily